<DOC>
	<DOC>NCT01559116</DOC>
	<brief_summary>The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of treatment.</brief_summary>
	<brief_title>Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: 1. Diagnosis of chronic obstructive pulmonary disease 2. Relatively stable airway obstruction with a postbronchodilator FEV1&lt; 80% of predicted normal and a postbronchodilator FEV1/FVC &lt;70% 3. Male or female patients, 40 years of age or older 4. Smoking history of more than 10 pack years 5. Ability to perform technically acceptable pulmonary function tests and maintain records 6. Ability to inhale medication in a competent manner from the RESPIMAT Inhaler and from a metered dose inhaler (MDI) Exclusion criteria: 1. significant disease other than COPD 2. clinically relevant abnormal lab values 3. history of asthma 4. diagnosis of thyrotoxicosis 5. diagnosis of paroxysmal tachycardia 6. history of myocardial infarction 7. unstable or lifethreatening cardiac arrhythmia 8. Hospitalization for heart failure within the past year 9. known active tuberculosis 10. malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years 11. history of lifethreatening pulmonary obstruction 12. history of cystic fibrosis 13. clinically evident bronchiectasis 14. history of significant alcohol or drug abuse 15. history of thoracotomy with pulmonary resection 16. oral or patch ßadrenergics 17. oral corticosteroid medication at unstable doses 18. regular use daytime oxygen therapy for more than one hour per day 19. Pulmonary rehabilitation program in the six weeks prior to the screening visit 20. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit 21. Known hypersensitivity to ßadrenergic drugs, BAC, EDTA 22. Pregnant or nursing women 23. Women of childbearing potential not using a highly effective method of birth control 24. Patients who have previously been randomised in this study or are currently participating in another study 25. Patients who are unable to comply with pulmonary medication restrictions prior to randomisation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>